Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications.
Hyperlipidemia is characterized by abnormally increased plasma of any or all lipids and /or lipoproteins and is a confirmed risk factor for the formation of atherosclerosis. Inflammation plays a crucial role in the formation and progression of atherosclerosis and consequently on cardiovascular diseases. Nowadays, the effective role of the immune system and subsequently of systemic inflammation is well established. Multiple levels of evidence from experimental models and histopathologic assessment of tissues to systemic biomarkers and epidemiologic or clinical associations have revealed that inflammation is one of the basic mechanisms in the destabilization of the atherogenetic plaque which leads to clinical events. Several inflammatory markers are affiliated with lipids level and the process of atherosclerosis. The most known of them are interleukin 6 and interleukin 1β, C-reactive protein, tumor necrosis factor-alpha, pentraxin3, serum amyloid A, sCD40, adhesion molecules, monocyte chemoattractant protein-1, sEndoglin, PAPP-A, chemokine 16, insulin like growth factor, lipoprotein-associated phospholipase A2 and galectin 3 but their role in atherogenesis is not well established for all of them. As atheromatosis is one of the main causes of death all over the world, in upcoming studies it will be useful to specify the exact role of these markers in this process in order to have a better prognosis, diagnosis and understanding of this disorder. The aim in this review is to study the literature on the novel inflammation markers of hyperlipidemia according to their clinical implications.